NovaBridge Biosciences (NBP) director Liu Xin files initial insider Form 3

Rhea-AI Filing Summary

NovaBridge Biosciences director Liu Xin filed an initial ownership report on Form 3. This filing establishes Liu Xin as a reporting insider of the company but does not list any stock transactions or detailed holdings. It is a routine compliance step required under insider reporting rules.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Liu Xin

(Last) (First) (Middle)

C/O NOVABRIDGE BIOSCIENCES,

2440 RESEARCH BOULEVARD, SUITE 400

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
NovaBridge Biosciences [ NBP ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit List: Ex. 24.1 - Power of Attorney

No securities are beneficially owned.

	/s/ Xi-Yong (Sean) Fu as attorney-in-fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Liu Xin's Form 3 filing mean for NovaBridge Biosciences (NBP)?

The Form 3 filing shows Liu Xin has become a reportable insider of NovaBridge Biosciences. It is a baseline disclosure of insider status and contains no share purchases, sales, or derivative positions, making it a routine regulatory compliance event rather than a trading signal.

Did Liu Xin buy or sell NovaBridge Biosciences (NBP) shares in this Form 3?

No, this Form 3 does not report any purchases, sales, or derivative exercises by Liu Xin. It only records insider status as a director at NovaBridge Biosciences, with transaction counts and share amounts all shown as zero in the filing summary data provided.

What role does Liu Xin hold at NovaBridge Biosciences (NBP) in this Form 3?

The filing identifies Liu Xin as a director of NovaBridge Biosciences and not as an officer or ten percent owner. Form 3 is required when someone becomes a director or other reporting person, establishing their obligation to disclose future transactions in the company’s securities.

Does Liu Xin have any reported derivative positions in NovaBridge Biosciences (NBP)?

The derivative section in this Form 3 is empty, and derivative-related transaction counts are zero. That means the filing does not list any options, warrants, or other derivative securities for Liu Xin, so no derivative holdings or exercises are disclosed in this initial ownership report.

Is Liu Xin considered a ten percent owner of NovaBridge Biosciences (NBP) in this filing?

No, the Form 3 indicates Liu Xin is not a ten percent owner of NovaBridge Biosciences. The reporting status is based on being a director only, which still requires ongoing disclosure of future trades but does not imply a large ownership stake from the information provided here.